Literature DB >> 20333432

Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology.

Takuro Shimbo1, Tsuguya Fukui, Chikashi Ishioka, Kohji Okamoto, Takahiro Okamoto, Shingo Kameoka, Atsushi Sato, Masakazu Toi, Kunihiko Matsui, Toshihiko Mayumi, Shigetoyo Saji, Masaru Miyazaki, Yuichi Takatsuka, Koichi Hirata.   

Abstract

BACKGROUND: The Japan Society of Clinical Oncology started implementing clinical practice guidelines for cancer in 2001. It created a Guideline Committee and has published cancer-related information in collaboration with individual subspecialty cancer societies. The society then established an Evaluation Committee to assess the quality of guidelines.
METHODS: The quality of development and general characteristics of guidelines were reviewed using the AGREE instrument. The six standardized domain scores and 23-item crude scores were described, and items with a low median score or a wide inter-quartile range were explored. Kappa statistics for inter-rater reproducibility were also described.
RESULTS: Domains in which the median score was >50 points in 18 guidelines developed between March 2005 and May 2009 included "scope and purpose," "rigor of development," and "clarity and presentation." Domains with a median score < 50 points were "stakeholder involvement," "applicability," and "editorial independence." Scores in all domains except "stakeholder involvement" were higher during the second half of the period than during the first half of the period, although P values were 0.10-0.93. Crude scores remained low for items 5, 7, 19, 20, 22, and 23, and the inter-quartile ranges of items 2, 6, 10, and 22 were wide. Kappa statistics ranged from -0.02 to 0.64, and they were especially low for items 3, 5, 7, 18, and 23.
CONCLUSION: Guideline quality has tended to improve during the 10 years since the society started this activity. However, issues remain to be improved through continuous revisions.

Entities:  

Mesh:

Year:  2010        PMID: 20333432     DOI: 10.1007/s10147-010-0060-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  2 in total

1.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project.

Authors: 
Journal:  Qual Saf Health Care       Date:  2003-02

2.  Reliability and validity of the AGREE instrument used by physical therapists in assessment of clinical practice guidelines.

Authors:  Joy C MacDermid; Dina Brooks; Sherra Solway; Sharon Switzer-McIntyre; Lucie Brosseau; Ian D Graham
Journal:  BMC Health Serv Res       Date:  2005-03-02       Impact factor: 2.655

  2 in total
  4 in total

1.  Questionnaire survey for the development and publication of cancer clinical practice guidelines in Japan.

Authors:  Tomohisa Furuhata; Koichi Hirata; Fumihiko Wakao; Kenji Okita; Masafumi Imamura; Yoshihiko Maehara; Masahiko Nishiyama
Journal:  Int J Clin Oncol       Date:  2014-06-26       Impact factor: 3.402

2.  Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

Authors:  Carmel Jacobs; Ian D Graham; Julie Makarski; Michaël Chassé; Dean Fergusson; Brian Hutton; Mark Clemons
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

Review 3.  Assessment of the quality of clinical practice guidelines in Korea using the AGREE Instrument.

Authors:  Min-Woo Jo; Jin Yong Lee; Nam-Soon Kim; Soo-Young Kim; Seungsoo Sheen; Seon Ha Kim; Sang-Il Lee
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

4.  Creation and provision of a question and answer resource for esophageal cancer based on medical professionals' reports of patients' and families' views and preferences.

Authors:  Yasushi Toh; Yoji Inoue; Masayo Hayakawa; Chikako Yamaki; Hiroya Takeuchi; Masaichi Ohira; Hisahiro Matsubara; Yuichiro Doki; Fumihiko Wakao; Tomoko Takayama
Journal:  Esophagus       Date:  2021-06-24       Impact factor: 4.230

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.